대한의용생체공학회:의공학회지 (Journal of Biomedical Engineering Research)

  • 제41권1호
  • /
  • Pages.62-66
  • /
  • 2020
  • /
  • 1229-0807(pISSN)
  • /
  • 2288-9396(eISSN)
대한의용생체공학회 (The Korean Society of Medical and Biological Engineering)
권호 표지
DOI QR코드

DOI QR Code

약물지연방출을 위한 스테레오컴플렉스 PLA 원반형 마이크로입자

Stereocomplex Poly(lactic acid) Discoidal Microparticles for Sustained Drug Release

  • 박채원 (연세대학교 보건과학대학 의공학부) ;
  • 박상효 (연세대학교 보건과학대학 의공학부) ;
  • 김우철 (연세대학교 보건과학대학 의공학부) ;
  • 기재홍 (연세대학교 보건과학대학 의공학부)
  • Park, Chaewon (Department of Biomedical Engineering, Yonsei University) ;
  • Park, Sanghyo (Department of Biomedical Engineering, Yonsei University) ;
  • Kim, Woo Cheol (Department of Biomedical Engineering, Yonsei University) ;
  • Key, Jaehong (Department of Biomedical Engineering, Yonsei University)
  • 투고 : 2019.09.09
  • 심사 : 2020.02.27
  • 발행 : 2020.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Controlled drug release is important for effective treatment of cancer. Poly(DL-lactide-co-glycolide) acid (PLGA) is a Food and Drug Administration (FDA) approved polymer and have been extensively studied as drug delivery carriers with biodegradable and biocompatible properties. However, PLGA drug delivery carriers are limited due to the initial burst release of drug. Certain drugs require an early rapid release, but in many cases the initial rapid release can be inefficient, reducing therapeutic effects and also increasing side effects. Therefore, sustained release is important for effective treatment. Poly Lactic Acid stereo complex (PLA SC) is resistant to hydrolysis and has high stability in aqueous solutions. Therefore, in this work, PLGA based discoidal polymeric particles are modified by Poly Lactic Acid stereocomplex (PLAsc DPPs). PLAsc DPPs are 3 ㎛ in diameter, also showing a relatively sustained release profile. Fluorescein 5(6)-isothiocyanate (FITC) released from PLAsc DPPs was continuously observed until 38 days, which showed the initial release of FITC from PLAsc DPPs was about 3.9-fold reduced as compared to PLGA based DPPs at 1 hour.

키워드

참고문헌

  1. TGJr CBR. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:6572.
  2. Singh RP, Sharma G, Singh S, Bharti S, Pandey BL, Koch B, Muthu MS. Chitosan-folate decorated carbon nanotubes for site specific lung cancer delivery. Materials Science and Engineering: C. 2017;77:446-58. https://doi.org/10.1016/j.msec.2017.03.225
  3. Mignani S, Bryszewska M, Klajnert-Maculewicz B, Zablocka M, Majoral J-P. Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report. Biomacromolecules. 2014;16:1-27. https://doi.org/10.1021/bm501285t
  4. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. European journal of pharmaceutics and biopharmaceutics. 2015;93:52-79. https://doi.org/10.1016/j.ejpb.2015.03.018
  5. Senapati S, Mahanta A.K, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal transduction and targeted therapy. 2018;3:7. https://doi.org/10.1038/s41392-017-0004-3
  6. Witharana C, Wanigasekara J. Drug Delivery Systems: A New Frontier in Nano-technology. International Journal of Medical Research & Health Sciences. 2017;6:11-4.
  7. Langer R. New methods of drug delivery. Science. 1990;249:1527-33. https://doi.org/10.1126/science.2218494
  8. Sonali, Agrawal P, Singh RP, Rajesh CV, Singh S, Vijayakumar MR, Pandey BL, Muthu MS. Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats. Drug delivery. 2016;23:1788-98. https://doi.org/10.3109/10717544.2015.1094681
  9. Bhirde AA, Patel V, Gavard J, Zhang G, Sousa AA, Masedunskas A, Leapman RD, Weigert R, Gutkind JS, Rusling JF. Targeted killing of cancer cells in vivo and in vitro with EGFdirected carbon nanotube-based drug delivery. ACS nano, 2009;3:307-16. https://doi.org/10.1021/nn800551s
  10. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chemical reviews. 1999;99:3181-98. https://doi.org/10.1021/cr940351u
  11. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. Journal of controlled release. 2001;73:121-36. https://doi.org/10.1016/S0168-3659(01)00248-6
  12. Setterstrom JA, Tice TR, Myers WE. Development of encapsulated antibiotics for topical administration to wounds. In Recent advances in drug delivery systems. 1984;185-98.
  13. Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. Journal of polymer science Part B: polymer physics. 2011;49:832-64. https://doi.org/10.1002/polb.22259
  14. Ikada Y, Jamshidi K, Tsuji H, Hyon SH. Stereocomplex formation between enantiomeric poly (lactides). Macromolecules. 1987;20:904-6. https://doi.org/10.1021/ma00170a034
  15. Monticelli O, Putti M, Gardella L, Cavallo D, Basso A, Prato M, Nitti S. New stereocomplex PLA-based fibers: effect of POSS on polymer functionalization and properties. Macromolecules. 2014;47:4718-27. https://doi.org/10.1021/ma500528a
  16. Regnell Andersson S, Hakkarainen M, Inkinen S, Sodergard A, Albertsson A-C. Customizing the hydrolytic degradation rate of stereocomplex PLA through different PDLA architectures. Biomacromolecules. 2012;13:1212-22. https://doi.org/10.1021/bm300196h
  17. Pastorino L, Dellacasa E, Petrini P, Monticelli O. Stereocomplex poly (lactic acid) nanocoated chitosan microparticles for the sustained release of hydrophilic drugs. Materials Science and Engineering:C. 2017;76:1129-35. https://doi.org/10.1016/j.msec.2017.03.170
  18. Xie G, Sun J, Zhong G, Shi L, Zhang D. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Archives of toxicology. 2010;84:183-90. https://doi.org/10.1007/s00204-009-0488-x
  19. Sarparanta M, Bimbo LM, Rytkonen J, Makila E, Laaksonen TJ, Laaksonen Pi, Nyman M, Salonen J, Linder MB, Hirvonen J. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Molecular pharmaceutics. 2012;9:654-63. https://doi.org/10.1021/mp200611d
  20. Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine. 2011;6:815-35. https://doi.org/10.2217/nnm.11.79
  21. Jindal AB. The effect of particle shape on cellular interaction and drug delivery applications of micro-and nanoparticles. International journal of pharmaceutics. 2017;532:450-65. https://doi.org/10.1016/j.ijpharm.2017.09.028
  22. Decuzzi P, Godin B, Tanaka T, Lee SY, Chiappini C, Liu X, Ferrari M. Size and shape effects in the biodistribution of intravascularly injected particles. Journal of Controlled Release. 2010;141:320-7. https://doi.org/10.1016/j.jconrel.2009.10.014
  23. Looney MR, Bhattacharya J. Live imaging of the lung. Annual review of physiology. 2014;76:431-45. https://doi.org/10.1146/annurev-physiol-021113-170331
  24. Yu T, Greish K, McGill LD, Ray A, Ghandehari H. Influence of geometry, porosity and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold. ACS nano. 2012;6:2289-301. https://doi.org/10.1021/nn2043803
  25. Park JY, Park S, Lee TS, Hwang YH, Kim JY, Kang WJ, Key J. Biodegradable micro-sized discoidal polymeric particles for lung-targeted delivery system. Biomaterials. 2019;218:119331, doi:10.1016/j.biomaterials.2019.119331.
  26. Mak WC, Richter H, Patzelt A, Sterry W, Lai KK, Renneberg R, Lademann J. Drug delivery into the skin by degradable particles. European journal of pharmaceutics and biopharmaceutics. 2011;79:23-7. https://doi.org/10.1016/j.ejpb.2011.03.021
  27. Liu Y, Miyoshi H, Nakamura M. Novel drug delivery system of hollow mesoporous silica nanocapsules with thin shells: preparation and fluorescein isothiocyanate (FITC) release kinetics. Colloids and Surfaces B: Biointerfaces. 2007;58:180-7. https://doi.org/10.1016/j.colsurfb.2007.03.005